Progress!A year ago they did a reverse take over with a publicly listed company. This solved the problem they previously had with getting the funding required for clinical trials without giving away too much of their equity and diluting their shareholders (which are mostly insiders).
Since then they have completed 3 phases of pre-clinical trials and intital results are promising. With a couple more reports coming this month. They also hired a high calibre Chief Medical Officer and entered into a couple of key partnership agreements.
Most exciting of all is that they have finally updated their web site, where you can find all of the information listed above and much more. and a very cool video illustration of how the lens works. The Investor brochure gives a very clear picture of the steps and the timeline moving forward. There is still further fundraising to be completed which will add to the outstanding share count, however, each succesful trial will show that they are on the verge of a disruptive change to the Intra-ocular lens market and to the ophthalmology industry as a whole and the share price will reflect that.